ADIM
TGTX icon

Alpha DNA Investment Management’s TG Therapeutics TGTX Stock Holding History

Alpha DNA Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-31,340
Closed -$778K – 219
2023
Q2 		$778K Buy
+31,340
New +$809K 0.26% 106

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Alpha DNA Investment Management's TGTX Position: Q3 2023 in Review

Alpha DNA Investment Management sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 31,340 shares — an estimated $778K sold.

Alpha DNA Investment Management first reported a position in TGTX in Q2 2023 and held it in 1 quarter. The position peaked at $778K in Q2 2023. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Alpha DNA Investment Management reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 31,340 TG Therapeutics shares in Q3 2023, an estimated $778K.
  • Alpha DNA Investment Management first reported a position in TG Therapeutics in Q2 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's TG Therapeutics position peaked at $778K in Q2 2023.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.